Cancer

Items 11-20 of 47

per page
Set Descending Direction
  1. CD38 (human) (rec.) (His) (active) (10µg)
    BBL-2275
    BBL-2275-C01010 µg
    CHF 782.00
    CD38 (human) (rec.) (His) (active) (10µg)
  2. DR6 (human):Fc (human) (rec)
    AG-40B-0011
    AG-40B-0011-C05050 µg
    CHF 170.00
    AG-40B-0011-30503 x 50 µg
    CHF 335.00
  3. Frizzled-5 (human):Fc (human) (rec.)
    AG-40B-0133
    AG-40B-0133-C05050 µg
    CHF 290.00
    AG-40B-0133-30503 x 50 µg
    CHF 575.00
    Figure: Frizzled-5 (human):Fc (human) (rec.) (AG-40B-0133) efficiently inhibits Wnt3a activation. Methods: Inhibition of Wnt3a activation by Frizzled-5 (human):Fc (human) (rec.) was measured by using HEK293 cells transfected with a plasmid c
  4. HA-Ubiquitin-propargylamide (human) (rec.) (HA)
    SBB-PS0124
    SBB-PS0124-C05050 µg
    CHF 366.00
    HA-Ubiquitin-propargylamide (human) (rec.) (HA)
  5. HA-Ubiquitin-vinyl methyl ester (human) (rec.) (HA)
    SBB-PS0123
    SBB-PS0123-C05050 µg
    CHF 366.00
    HA-Ubiquitin-vinyl methyl ester (human) (rec.) (HA)
  6. HA-Ubiquitin-vinyl pentyl sulfone (human) (rec.) (HA)
    SBB-PS0125
    SBB-PS0125-C05050 µg
    CHF 366.00
    HA-Ubiquitin-vinyl pentyl sulfone (human) (rec.) (HA)
  7. HA-Ubiquitin-vinyl sulfone (human) (rec.) (HA)
    SBB-PS0122
    SBB-PS0122-C05050 µg
    CHF 366.00
    HA-Ubiquitin-vinyl sulfone (human) (rec.) (HA)
  8. ISG15 (human) (rec.) (Rhodamine 110)
    SBB-PS0002
    SBB-PS0002-C05050 µg
    CHF 434.00
    Signal to Background. The signal to background ratio was determined by 100% hydrolysis of either 50nM or 500nM ISG15-Rhodamine 110 to liberate the quenched conjugate. Assay Buffer: 50mM HEPES pH7.5, 100mM NaCl, 1mM TCEP, 0.1mg/ml BSA.
  9. K11-linked Di-Ubiquitin (human) (rec.) (untagged)
    SBB-UP0063
    SBB-UP0063-C02525 µg
    CHF 184.00
  10. K11-linked Tetra-Ubiquitin (human) (rec.) (untagged)
    SBB-UP0064
    SBB-UP0064-C02525 µg
    CHF 278.00

Items 11-20 of 47

per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.